KURT HEINTZELMAN: Open Payments
NPI 1598096950 · COLUMBUS, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,675 in 241 payments from 17 companies in 2025. Trend: 2023 $2,256 · 2024 $2,218 · 2025 $3,675
Food & beverage: $3,675
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 37 | $678 |
| E.R. Squibb & Sons, L.L.C. | 32 | $585 |
| Vanda Pharmaceuticals Inc. | 28 | $572 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 31 | $450 |
| Alkermes, Inc. | 32 | $365 |
| Otsuka America Pharmaceutical, Inc. | 21 | $288 |
| Teva Pharmaceuticals USA, Inc. | 19 | $241 |
| ABBVIE INC. | 24 | $221 |
| Lundbeck LLC | 4 | $62 |
| Almatica Pharma LLC | 3 | $50 |
Products named: INGREZZA, COBENFY, CAPLYTA, HETLIOZ, ARISTADA, UZEDY, VRAYLAR, REXULTI.
Industry payments across OH — which companies pay providers there.
